Onkogenoks is the brand of the Genoks Genetic Diseases Evaluation Center focused on cancer genetics and precision oncology solutions. Using Next-Generation Sequencing (NGS) technologies, it offers hereditary cancer panels, comprehensive genomic profiling, liquid biopsy, and solid tumor panels to analyze both hereditary and somatic mutations in detail. This provides a scientific foundation for identifying cancer risks, planning personalized treatment strategies, and avoiding unnecessary therapies.
A comprehensive approach to cancer genetics. Onkogenoks is the Genoks Genetic Diseases Evaluation Center’s brand dedicated to oncology and cancer genetics. Using Next-Generation Sequencing (NGS)–based hereditary cancer panels, tumor mutation analyses, comprehensive genomic profiling, and liquid biopsy tests, it thoroughly investigates the genetic basis of cancer.
From risk assessment to treatment planning. Tests such as BRCA, HRR/HRD, prostate, and colorectal cancer panels reveal both hereditary cancer susceptibility and genetic alterations present in existing tumors. This enables the planning of early screening strategies and supports eligibility for targeted therapies and immunotherapy based on genomic data.
Personalized oncology that reduces unnecessary treatments. Onkogenoks tests identify the molecular signature of the tumor, indicating which treatments are most likely to be beneficial and helping to avoid low-response or unnecessary therapies. Results are presented in clear, clinician- and patient-friendly reports.
Precision oncology guided by genetic diagnosis.
Through hereditary and somatic cancer testing, Onkogenoks provides genomic guidance throughout the entire process—from risk assessment to treatment selection—supporting a personalized oncological approach tailored to the genetic profile of each patient.
We evaluate genetic alterations associated with hereditary and somatic cancers through BRCA, HRR/HRD, comprehensive hereditary panels, and deep genomic profiling tests. All processes are carried out in Genoks laboratories in Türkiye in line with current quality standards.
Hereditary cancers are associated with inherited mutations in tumor suppressor genes and DNA repair genes. A hereditary cancer predisposition may be considered when the same cancer type occurs in multiple family members, different cancer types are frequently observed within the family, or cancer is diagnosed at an early age.
Onkogenoks’ genoXhere panels include BRCA, breast/ovarian, prostate, colon, prime, and plus panels. With gene content curated according to current scientific evidence, they provide comprehensive assessment options for hereditary cancers.
The test groups below cover a broad spectrum—from hereditary cancer panels to comprehensive genomic profiling.
The scope and intended use of each panel should be evaluated within the framework of the related technical documentation.
You can access details by clicking the corresponding cards.
638 DNA genes + 22 RNA driver genes · SNV, indel, CNV, HRD, MSI, TMB, fusions
Designed by oncology experts with clinical targets in mind, the GenoXonco-Plus panel is optimized to cover the most critical actionable alterations in solid tumors. Genomic alterations and complex signatures are presented together in a single report.
SNV, indel, CNV and LOH analysis across 638 genes.
Fusions and abnormal splicing events across 22 driver genes.
Genomic signatures such as HRD, MSI, and TMB are included.
FFPE tissue sample · NGS-based hybrid-capture library preparation.
15 HRR genes · Genomic Instability Score · CE-IVD and clinical validation
Onkogenoks HRD evaluates homologous recombination deficiency using BRCA1/2 plus 13 additional HRR-related genes. It reports a clear HRD positive or negative result together with the Genomic Instability Score (GIS), supporting planning of targeted therapies such as PARP inhibitors.
74 genes · Whole CDSs, hotspots, translocation and abnormal splicing genes
GenoxLiquid analyzes plasma-derived ctDNA in patients with solid tumors. The panel screens a broad gene set associated with targeted and hormonal therapies, assessing SNVs, indels, CNVs, TERT promoter mutations, intronic fusion events, abnormal splicing events, and complex genomic signatures such as HRR/MSI.
Detects hereditary pathogenic variants in BRCA1 and BRCA2. Supports hereditary risk assessment in BRCA-associated cancers, especially breast and ovarian cancer.
Includes analysis of 25 genes associated with hereditary breast-ovarian cancer syndrome. In addition to BRCA1/2, the panel covers ATM, BRIP1, CDH1, CHEK2 and other related genes.
Evaluates 12 genes associated with hereditary prostate cancer. BRCA1/2, ATM, CHEK2, DNA repair pathway genes and mismatch repair genes are included.
Includes analysis of 22 genes associated with hereditary colorectal cancers, including Lynch syndrome and familial adenomatous polyposis; genes such as MLH1, MSH2, MSH6 and APC are included.
A broad hereditary panel screening 170 genes associated with increased cancer risk using NGS. Enables simultaneous evaluation of genes associated with different organs and syndromes.
Includes analysis of 360 genes associated with predisposition to hematologic cancers in addition to solid tumors. With extensive gene content, it supports detailed assessment across the hereditary oncology spectrum.
Hereditary pathogenic variants in BRCA1 and BRCA2 are associated with increased risk not only for breast and ovarian cancer, but also for other cancer types such as prostate, pancreatic and melanoma. The genoXhere-BRCA test evaluates mutations in these two genes using next-generation sequencing and contributes to planning appropriate screening strategies.
| Sample type | EDTA blood or DNA |
| Number of genes | 2 (BRCA1, BRCA2) |
| Platform / method | Illumina / MGI / NGS |
Hereditary breast-ovarian cancer syndrome is associated with increased risk of breast and ovarian cancer, as well as prostate, pancreatic and melanoma cancers. Using next-generation sequencing, the genoXhere-breast/ovarian panel analyzes 25 genes including BRCA1 and BRCA2, as well as ATM, BRIP1, CDH1 and CHEK2.
| Sample type | EDTA blood or DNA |
| Number of genes | 25 |
| Platform / method | Illumina / MGI / NGS |
The genoXhere-prostate panel analyzes 12 genes known to be associated with hereditary prostate cancer using next-generation sequencing.
| Sample type | EDTA blood or DNA |
| Number of genes | 12 |
| Platform / method | Illumina / MGI / NGS |
The genoXhere-colon panel analyzes a total of 22 genes using next-generation sequencing, including MLH1, MSH2 and MSH6 (genes associated with Lynch syndrome), as well as APC (associated with familial adenomatous polyposis).
| Sample type | EDTA blood or DNA |
| Number of genes | 22 |
| Platform / method | Illumina / MGI / NGS |
The genoXhere-prime test consists of 170 genes known to be associated with hereditary cancer syndromes and increased cancer risk. Using next-generation sequencing, it evaluates mutations that may increase cancer risk.
| Sample type | EDTA blood or DNA |
| Number of genes | 170 |
| Platform / method | Illumina / MGI / NGS |
The genoXhere-plus panel analyzes 360 genes known to be associated with predisposition to hematologic cancers in addition to solid tumors.
| Sample type | EDTA blood or DNA |
| Number of genes | 360 |
| Platform / method | Illumina / MGI / NGS |
BRCA, breast/ovarian and HRR/HRD panels jointly evaluate genes associated with hereditary breast and ovarian cancers. In gynecologic oncology practice, they support planning treatment options such as PARP inhibitors.
POLE, P53, MMR deficiency and MSI are key biomarkers used in the molecular classification of endometrial cancer. This classification helps personalize follow-up intensity and treatment options.
Founded in 2008 as an R&D laboratory, Genoks provides genetic testing across a broad portfolio including WGS, WES, cancer genetics, carrier screening, newborn screening, single-gene disorders, metabolic and neurodegenerative diseases, ophthalmic genetics and pharmacogenetics.
With a comprehensive NGS database and international collaborations, Genoks aims to be one of the leading genomic centers in the region.
For detailed information, panel selection or genetic counseling regarding Onkogenoks oncology tests, please contact us via:
